Nurse offers more details on Subsys kickbacks; Zydus Cadila boosts U.S. sales 25%;

@FiercePharma: Parnell shares advance on strong Q3 revenue growth. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: After shutting plant over mold issues, France's decides using CMOs makes more sense. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Good news for Allergan: Men want to treat wrinkles. Bad? They're clueless about products. FiercePharmaMarketing article | Follow @CarlyHFierce

> New court documents detail the kickbacks a nurse allegedly received to boost scripts of the Insys painkiller Subsys. Report | More

> India's Zydus Cadila reported a 41% rise in quarterly profits, partly fueled by 25% sales growth in the U.S. Report

> Members of the military insurance program Tricare have run into prescription-filling problems, including scripts for common heart meds, because of drug shortages. Report

> Script numbers hint that Amgen's ($AMGN) PCSK9 drug Repatha may be gaining on Sanofi ($SNY) and Regeneron's ($REGN) Praluent, but it's early days yet for both launches. Report

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Silk Road reels in $57M to commercialize its system for stroke prevention. Article | Follow @VarunSaxena2

@EmilyWFierce: Subway ups the ante on antibiotic-free meat pledge. FierceAnimalHealth story | Follow @EmilyWFierce

> Masimo unveils smart glasses patient monitoring tech. News

> Qualcomm's newly acquired Capsule launches smart patient monitoring system. More

Biotech News

@FierceBiotech: Gene therapy for brain protein boosts memory in aged mice. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Moderna launches the 3rd or 4th personalized cancer vaccine co. in a month. Release | Follow @JohnCFierce

@DamianFierce: Casting the Coen Bros. $VRX movie: Clooney obviously plays Ackman, and then maybe John Goodman for Pearson. William H. Macy as Pyott? | Follow @DamianFierce

> AIT pushes ahead with plans for $40M Nasdaq IPO. Report

> Relypsa wins patiromer OK but gets hammered on black box restrictions. Story

> Moderna joins the personalized cancer vaccine rush with third new venture. Article

> FierceBiotech Radio on doomsdays for Valeant, Biogen and biotech VC. More

CRO News

> Quintiles pairs up with IMS to use real-world data in Phase III trials. Report

> BioClinica revamps its CRO partner program. Item

> SRI inks a $100M contract with NIH to study treatments for radiation exposure. More

> Quintiles shuffles its C-suite with new CFO, COO. News

> Evotec partners up for rare disease R&D in a discovery deal. Article

Pharma Manufacturing News

> Roche partner Chugai significantly expanding antibody capacity at Japan plant. Story

> Biogen's manufacturing feels the pain of its cost-cutting. Report

> Perrigo to consolidate supply chain operations as part of downsizing. Item

> Feds get guilty pleas from suppliers in massive drug diversion operation. More

> AstraZeneca opens plant in Russia. News

Pharma Asia News

> Abbott still eager for emerging markets, but currency headwinds an issue. Article

> Asia's dengue epidemic highlights race for treatment, vaccine options. More

> Chinese hackers said to target U.S. tech and pharma companies. Report

> BeiGene heads to Nasdaq with $100M IPO in China oncology boom. Story

> Yabao expands ties in diabetes pact with a busy Eli Lilly in China. Article

And Finally... Hospital routines may make patients sicker, a study found. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.